|
Objective: To detect the B-cell activating factor (B cells activating factor of the TNF ligand family, BAFF) in B-cell hematological malignancies, including acute lymphoblastic leukemia (acute lymphocytic leukemia, ALL), chronic lymphocytic leukemia (chronic lymphocytic leukemia CLL), multiple myeloma (multiple myeloma, MM), lymphoma (Lymphoma) plasma concentration; compare disease before and after treatment plasma soluble BAFF protein concentration in change; analysis of the correlation between BAFF and B-cell malignancies clinical tumor burden sex. Methods: Study subjects: 41 patients with ALL, 34 CLL patients, 42 patients with MM, 46 cases of lymphoma patients and 15 healthy subjects as normal control group. ALL patients, 41 cases, male 24 cases, 17 females, age range 16 to 71 years old, with a median age of 28 years, the initial treatment in 16 patients, eight cases of relapse, remission, 17 patients. CLL in 34 patients, 19 males and 15 females, age range 40 to 83 years old, with a median age of 66 years, the naive 10 cases, 24 cases after treatment. MM 42 patients, 19 males and 23 females, age range 41 to 85 years old, with a median age of 57 years old, the initial treatment in 13 cases, 20 cases of remission after treatment, nine cases of remission after treatment. Lymphoma in 46 patients, 25 males and 21 females, age range 15 to 74 years, with a median age of 54 years old, naive, 17 cases, 29 cases after treatment. Normal control group, 15 cases were taken from the crowd of a routine physical examination normal, 8 males and 7 females, ages ranging from 18 to 69 years, with a median age of 42 years old. 2 Research Methods: ELISA (Enzyme-linked Immunosorbent Assay, ELISA) method to detect the expression of various subjects plasma soluble BAFF collect patients with basic clinical data were analyzed. Results: 1 plasma soluble BAFF expression in each group 1.1 ALL plasma BAFF content of the treatment group than the normal control group, there was significant difference between the two groups (1513.156 ± 191.211 VS 824.884 ± 117.019, P lt; 0.01) ; ALL relapse group plasma BAFF content higher than the normal control group, there was significant difference between the two groups (1617.669 ± 164.218 VS 824.884 ± 117.019, P lt; 0.01); ALL remission group plasma BAFF content is higher than the normal control group, difference between the two groups was not statistically significant (993.313 ± 155.578VS 824.884 ± 117.019, P gt; 0.05); ALL-naive group the plasma BAFF content lower than the recurrence group, the difference between the two groups was not statistically significant (1513.156 ± 191.211 VS 1617.669 ± 164.218, P gt; 0.05); ALL remission group plasma BAFF content is lower than the initial treatment group, there was significant difference between the two groups (993.313 ± 155.578 VS 1513.156 ± 191.211, P lt; 0.01); ALL the plasma BAFF content lower than the relapse group remission group differences between the two groups was statistically significant (993.313 ± 155.578 VS 1617.669 ± 164.218, P lt; 0.01). The plasma BAFF content of the initial treatment group 1.2 MM higher than the normal control group, there was significant difference between the two groups (1603.693 ± 197.406 VS 824.884 ± 117.019, P lt; 0.01); MM after treatment without remission group plasma BAFF content higher than normal control group, the difference between the two groups was statistically significant (1584.340 ± 271.1214 VS 824.884 ± 117.019, P lt; 0.01); MM therapy after remission plasma BAFF levels higher than the normal control group, no difference between the two groups statistically significant (909.183 ± 118.353 VS 824.884 ± 117.019, P gt; 0.05); MM after treatment without remission plasma BAFF content is lower than the initial treatment group, the difference between the two groups was not statistically significant (1584.340 ± 271.121 VS 1603.693 ± plasma BAFF content 197.406, P gt; 0.05); MM therapy after remission group below the initial treatment group, there was significant difference between the two groups (909.183 ± 118.353 VS 1603.693 ± 197.406, P lt; 0.01); MM after treatment non-remission group the remission group plasma BAFF content is less than after treatment, there was significant difference between the two groups (909.183 ± 118.353 VS 1584.340 ± 271.121, P lt; 0.01). The plasma BAFF content of 1.3 lymphoma initial treatment group compared with normal controls, there was significant difference between the two groups (1592.208 ± 162.594 VS 824.884 ± 117.019, P lt; 0.01); lymphoma after treatment of plasma BAFF content is higher than normal control group, the difference between the two groups was statistically significant (1302.012 ± 183.685 VS 824.884 ± 117.019, P lt; 0.01); the plasma BAFF content is lower than the initial treatment group lymphoma treatment, the difference between the two groups have statistically significant (1302.012 ± 183.685 VS 1592.208 ± 162.594, P lt; 0.01). 1.4 CLL plasma BAFF content of the initial treatment group compared with normal controls, no statistically significant difference between the two groups (1223.980 ± 170.887 VS 824.884 ± 117.019, P gt; 0.05); the CLL treatment group plasma BAFF content is higher than normal control group, the difference between the two groups was not statistically significant (870.574 ± 159.433 VS 824.884 ± 117.019, P gt; 0.05); plasma BAFF content is lower than the initial treatment group CLL treatment group difference was statistically significant between the two groups (870.574 ± 159.433 VS 1223.980 ± 170.887, P lt; 0.01). 2 ALL, MM, lymphoma, CLL groups plasma BAFF content and serum LDH levels between the correlation coefficients were -0.046, -0.019,0.173,0.251, were not statistically significant. 3 ALL, the correlation coefficient between the MM, lymphoma, CLL groups plasma BAFF content and serum β2-MG content were 0.501,0.177,0.071,0.664 plasma the BAFF and serum β2-MG of ALL and CLL group a positive correlation, I No statistically significant. 4 MM plasma BAFF content of plasma cells in the bone marrow percentage correlation coefficient of 0.388, statistically significant. 5 MM plasma BAFF content and serum Ig correlation coefficient was 0.117, not statistically significant. Conclusion: 1 plasma BAFF content in newly diagnosed or relapsed ALL, MM, lymphoma group were high expression, suggesting that BAFF may be involved in the B cells in the pathogenesis of hematological malignancies, which play a role. The 2 plasma BAFF content in remission after treatment of ALL, MM and CLL after treatment group were significantly decreased, indicating that BAFF dynamic changes in hematological malignancies of the B-cell stage, want to use as ALL, MM, CLL therapy recurrence monitoring indicators. The 3 plasma BAFF content in previously untreated CLL group had no obvious expression after treatment is still higher than the normal control group, speculated that BAFF in B-cell malignant blood disease mainly by acting on mature B lymphocytes play a role. 4 ALL, MM, lymphoma of CLL by plasma BAFF content and LDH were not related, except CLL group and ALL group, the plasma BAFF content and β2-MG were not correlated, MM plasma BAFF content of bone marrow plasma cells. accounted for the percentage of positive correlation between unrelated Ig. Our experimental data show that is not able to BAFF considered judgment the above the disease tumor burden and prognosis of independent indicators.
|